All currency values in $ millions unless otherwise noted
| Income Statement | DEC 2025 | DEC 2024 57:1 split | DEC 2023 |
|---|---|---|---|
| General & Administrative | $36 | $30 | $12 |
| Research & Development | $134 | $112 | $50 |
| Total Operating Expenses | $170 | $143 | $62 |
| Operating Income | -$170 | -$143 | -$62 |
| Non-Operating | |||
| Net Interest Expense | $9 | $15 | $2 |
| Other Non-Operating Income (Expense) | $9 | $15 | $2 |
| Income Tax Expense | $0 | $0 | $0 |
| Net Income | |||
| Net Income | -$161 | -$127 | -$60 |
| EPS (Basic) | -$3.64 | -$3.33 | -$89.61 |
| EPS (Diluted) | -$3.64 | -$3.33 | -$89.61 |
| Weighted Avg Shares (Basic) | 44.3M | 38.3M | 673,622 |
| Weighted Avg Shares (Diluted) | 44.3M | 38.3M | 673,622 |
| Shares Outstanding | 44.3M | 38.3M | 673,622 |
Kyverna Therapeutics (KYTX) financials: revenue, profit and margins
Kyverna Therapeutics (KYTX) generated about n/a in revenue and -$153 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Kyverna Therapeutics profitable?+
Kyverna Therapeutics reported about -$153 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
SourceFinancial statements computed from the 10-Q filed 3 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Aug 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with KYTX
Held by ETFs
KYTX is in 14 US ETFs. The largest of them, with KYTX's weight in each:
iShares Biotechnology ETFIBB0.02%of the fund
Fidelity Enhanced Small Cap ETFFESM0.01%of the fund
State Street SPDR S&P Kensho New Economies Composite ETFKOMP0.06%of the fund
Avantis U.S. Small Cap Equity ETFAVSC0.02%of the fund
iShares Micro-Cap ETFIWC0.06%of the fund
Vanguard Russell 2000 Value Index FundVTWV0.02%of the fund
Spot a number that looks wrong? Check it in KYTX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing KYTX
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.